Aussie CSL Try To Acquire Talecris Of U.S. In Hands Of High-Profile Judge
This article was originally published in PharmAsia News
Executive Summary
The attempt of Australia's CSL to acquire Talecris Biotherapeutics of the United States apparently is going to be decided by a U.S. judge familiar with politically charged trials. The U.S. Federal Trade Commission has objected to allowing the merger because of antitrust issues, and has laid out its complaints in details that have not been disclosed. CSL and Talecris expect to move to keep the complaint sealed and hearing the case would be Judge Colleen Kollar-Kotelly, the same judge who presided over the Microsoft antitrust case and who has handled several U.S. terrorism cases. CSL is concerned that unsealing the FTC complaint would reveal sensitive information about the blood-plasma industry and CSL itself. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.